SecBot SecBot

INBS

INTELLIGENT BIO SOLUTIONS INC.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001725430 Healthcare & Medical Devices
$1.64 +0.05 (+3.14%)
Oct 26 4:00 PM ET · prev $1.59
Market cap
$5.6M
Nano cap
Median target
$12.00
+632% · range $12.00–12.00
1 year
−83.6%
from $10.00 · Oct 27
30 days
−0.6%
from $1.65
52-week range
$1.44–17.92
−91% from high · low Oct 15
Avg volume 20D
47.2K
Oct 13 spike 213.9K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 3 bearish · 1 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 5/11
Strongest BEARISH Intelligent Bio Solutions Inc. entered into a securities purchase agreement on August 31, 2026, to raise…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM20,840$47.8K
UBS Group AGDOUBLED5,735$13.2K
UBS Group AGNEAR_EXIT372$1.2K
VANGUARD GROUP INCDOUBLED97,686$99.6K
UBS Group AGTRIM300$516.00
GEODE CAPITAL MANAGEMENT, LLCADD49,012$70.6K
UBS Group AGTRIM1,172$1.7K
BANK OF AMERICA CORP /DE/ADD45$65.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12-month targets · 1 analysts

Price is below the lowest target. Median implies +632%.Targets as of Oct 27, 2026.

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Mar 18, 2026
Simeonidis Harry
Chief Executive Officer
AWARD21,350 sh
Mar 18, 2026
Isenberg Jason
Director
AWARD5,000 sh
Mar 18, 2026
Sakiris Spiro Kevin
Chief Financial Officer
AWARD21,350 sh
Mar 18, 2026
Boyages Steven Constantine
Director
AWARD5,000 sh
Mar 18, 2026
Fraser Nicola Marion
Director
AWARD5,000 sh
Mar 18, 2026
Hurd Jonathan Scott
Director
AWARD5,000 sh
Mar 18, 2026
Simeonidis Harry
Chief Executive Officer
AWARD9,150 sh
Mar 18, 2026
Sakiris Spiro Kevin
Chief Financial Officer
AWARD9,150 sh

Earnings setup

Estimates
−$1.31
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.31-$1.31–-$1.31+0.0%$1.4M
Next Q-$1.36-$1.36–-$1.36+0.0%$1.4M
Current FY-$5.18-$5.18–-$5.18+0.0%$6.1M
Next FY-$4.06-$4.06–-$4.06+0.0%$8.8M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Intelligent Bio Solutions Inc. filed Amendment No. 1 to its FY2026 10-K to correct non-financial disclosure items…
10-K/A — Impact 3/10
Oct 13, 2026 SEC
Intelligent Bio Solutions Inc. filed an 8-K reporting the adoption of Second Amended and Restated Bylaws (effective…
8-K — Impact 2/10
Sep 24, 2026 SEC
Intelligent Bio Solutions Inc.'s shelf registration statement (S-3, File No. 333-298951) became effective on September…
EFFECT — Impact 5/10
Sep 9, 2026 Other
Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance
Submission package includes Method Comparison Study, which delivered accuracy above 98%, sensitivity
Aug 17, 2026 Press
Intelligent Bio Solutions announced its Intelligent Fingerprinting Drug Screening business has been recertified to ISO…
Impact 4/10
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
20,840 shares ($47.8K)
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
5,735 shares ($13.2K)
Jun 16, 2026 Press
Intelligent Bio Solutions initiated an Interference Study to support its FDA 510(k) submission for the Intelligent…
Impact 3/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 9, 2026
Press release
Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance
Submission package includes Method Comparison Study, which delivered accuracy above 98%, sensitivity above 94%, and 100% specificity across three…
Aug 19, 2026
Earnings
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth
Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units
Aug 17, 2026
FDA
Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification
Recertification aligns with the FDA's newly amended Quality Management System Regulation and supports the Company's regulatory strategy as it…
Jul 21, 2026
Press release
Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market
Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites Precision…
Jun 16, 2026
FDA
Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world…

SecBot reports

14 filings · 3 press releases · 2 bullish · 3 bearish · 9 neutral
All INBS filing & press-release reports (17)